This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Bristol-Myers Squibb Company

Drug Names(s): Anti-PSMA

Description: MDX-070 is a fully human antibody,thattargets Prostate Specific Membrane Antigen, or PSMA. PSMA is a cell surfacemarker that is preferentially expressed on normal prostate tissue on malignantprostate tissues, and also on blood vessels in other tumors. Preclinical data suggests that the antibody will target live prostate tumor cells.

Deal Structure: MDX-070 is developed in collaboration with Northwest Biotherapeutics.

In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash. The acquisition was closed in September 2009.

Partners: Northwest Biotherapeutics, Inc.

MDX-070 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug